Latest news with #Editas
Yahoo
a day ago
- Business
- Yahoo
Editas Surpasses Therapeutic Gene Editing Threshold in New Preclinical Data
Editas Medicine, Inc. (NASDAQ:EDIT) ranks among the best CRISPR stocks to buy. At the European Hematology Association 2025 Congress on June 12, Editas Medicine, Inc. (NASDAQ:EDIT) revealed new in vivo data showing notable progress in gene editing for beta thalassemia and sickle cell disease. According to the study, a single dose of the company's proprietary targeted lipid nanoparticle (tLNP) in non-human primates exceeded the therapeutic threshold by achieving a mean on-target editing level of 58% in the HBG1/2 promoter region of hematopoietic stem cells. Editas' position in the gene editing market is strengthened by the result, enhancing the company's potential to offer a novel treatment for these illnesses with favorable biodistribution and minimal liver targeting. A clinical-stage biotechnology company, Editas Medicine, Inc. (NASDAQ:EDIT) develops gene-editing treatments that use CRISPR technology to modify patients' genomes to treat genetic diseases. Editas distinguishes itself from other major biotech companies that are seeking alternative genomic therapeutics by using an 'in vivo gene editing upregulation strategy.' While we acknowledge the potential of EDIT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.
Yahoo
17-06-2025
- Business
- Yahoo
Editas Medicine Is Great. Here's Why You Shouldn't Buy It.
The clinical-stage biotech is developing gene-editing CRISPR technology. Editas has reported encouraging testing results in laboratory animals. Still, the stock remains speculative amid uncertainties and challenges. 10 stocks we like better than Editas Medicine › The biotechnology sector is a thrilling arena for investors, with a history of delivering groundbreaking medical innovations that have led to massive shareholder returns. Editas Medicine (NASDAQ: EDIT) is a promising clinical-stage company that has captured Wall Street's attention at the forefront of the gene-editing revolution with a unique approach to CRISPR technologies. On the other hand, Editas faces a long road ahead before delivering its first Food and Drug Administration (FDA) approved therapy and reaching its goal of transforming into a commercially sustainable biotech. The stock, with a market capitalization of $170 million, has also been extremely volatile, down 62% over the past year despite a sharp 32% rebound in the past month as of this writing. Here's why you should proceed with caution if you're thinking about buying shares of Editas Medicine for your portfolio. Editas Medicine is developing a CRISPR gene editing system to address serious and rare conditions, such as sickle cell disease, beta thalassemia, and inherited eye disorders. Acting like molecular scissors, the CRISPR/Cas9 technology uses proteins to target specific DNA sequences in a person's genetic code, precisely addressing diseases caused by genetic mutations. More than just a treatment, this personalized medicine aims to deliver durable, curative solutions. Compared to larger biotech players pursuing alternative genomic therapies, Editas stands out with its "in vivo gene editing upregulation strategy." Rather than solely removing or replacing defective genes in the more traditional ex vivo approaches, Editas' method edits DNA directly in the body to enhance beneficial gene expression. In vivo gene editing represents a simplified treatment process without the need for cell extraction and harvesting required in ex vivo solutions. This means in vivo could prove more scalable and cost-effective. Early tests have shown encouraging results. Editas successfully edited blood stem cells in monkeys with one dose and increased a key liver protein in mice, which could help treat diseases. The plan is to formally declare two in vivo development candidates from a group of target cell types or tissues under research this year and launch at least one in vivo human clinical trial by the second half of 2026. The opportunity for Editas is to potentially deliver a first-to-market and best-in-class platform with applications for a wide range of genetic diseases. Before getting too excited about Editas Medicine as an investment, it's important to recognize that the company has substantial work ahead and faces significant technical challenges, including confirming a precise in vivo delivery mechanism and addressing off-target DNA risks. Research and development (R&D) partnerships with companies like Bristol Myers Squibb help validate the science and provide credibility to Editas Medicine's endeavors; yet, the in vivo gene editing approach has not been proven in humans. Reaching statistically significant efficacy and safety thresholds is far from certain. Even in a best-case scenario, Editas could still be several years away from a clear timeline for bringing a new therapy to market. Meanwhile, companies like CRISPR Therapeutics, Beam Therapeutics, and Intellia Therapeutics are all exploring in vivo CRISPR technologies, underscoring the highly competitive field. It's unclear whether Editas has an edge. More pressing for investors is reconciling Editas' weak fundamentals. In the first quarter, the company posted a net loss of $76.1 million, which included a $41 million restructuring charge as it abandoned its ex vivo program, pivoting exclusively to the in vivo strategy. This follows $390 million in negative net income between 2023 and 2024. The expectation is for recurring losses in the foreseeable future. With $221 million in cash on the balance sheet, company management believes it has the liquidity to continue development until mid-2027. Nevertheless, additional funding will likely be necessary to advance into late-stage development, including measures dilutive to shareholders. Any setback in the R&D process or regulatory timeline could force a reset of expectations and send the stock price lower. Balancing the pros and cons of investing in Editas Medicine, I believe the stock is simply too speculative to buy with conviction, as the risks outweigh the upside. The prudent approach is to avoid it, instead focusing on companies with higher-quality fundamentals, including steady growth and consistent profitability. Before you buy stock in Editas Medicine, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Editas Medicine wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,821!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $886,880!* Now, it's worth noting Stock Advisor's total average return is 791% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Dan Victor has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Beam Therapeutics, CRISPR Therapeutics, and Intellia Therapeutics. The Motley Fool recommends Editas Medicine. The Motley Fool has a disclosure policy. Editas Medicine Is Great. Here's Why You Shouldn't Buy It. was originally published by The Motley Fool
Yahoo
16-05-2025
- Business
- Yahoo
A new CFO tasked with taking ‘scrappy' Editas from last year's layoffs into new gene editing territory
This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Welcome to First 90 Days, a series dedicated to examining how pharma executives and other leaders are planning for success in their new roles. Today, we're speaking to Amy Parison, CFO at Editas Medicine, which is undergoing a shift in focus to in vivo therapies and navigating the many challenges of the gene editing space. Gene editing biotech Editas Medicine is no stranger to the drug development pivot. And along with a major reorganization and scientific focal shift, the company has put its financial decisionmaking in the hands of a first-time CFO while it gears up for the next phase. After a cost-cutting shuffle announced at the end of last year in which the company slashed roughly 65% of its workforce, Editas switched gears from an ex vivo gene editing platform to in vivo technology. The change moves the therapeutic process from an external procedure in a lab to one that's delivered directly into a patient. Editas' previous lead ex vivo candidate in sickle cell anemia wasn't a clinical failure. Rather, the drug, called reni-cel, suffered from a lack of a commercial partner, leading to a cash crunch at Editas. Now back to the drawing board, the company is focusing on preclinical candidates using hematopoietic stem cells in diseases like sickle cell and beta thalassemia as well as liver-directed gene editing, all with the more convenient and practical application of in vivo delivery. Navigating the transition is newly minted CFO Amy Parison who, after working as head of finance alongside the company's former CFO, took the reins at the end of March. "In biotech, you grow numb to operating at a loss. You're thinking more about cash runway and how to extend that." Amy Parison CFO, Editas Medicine Tasked with launching into the company's new focus, Parison looks at Editas as a 'scrappy' biotech willing to change its priorities to match the moment. Gene editing has long been a tricky area both in terms of the complex science and the financial calculus it takes to pull it off. Here, we spoke to Parison about Editas' unique position in the gene editing space, what lies ahead for a CFO managing a platform shift while maintaining a cash runway, and some of the potential political and financial snags the company could face as it heads in this new direction. This interview has been edited for brevity and style. AMY PARISON: What jumps out to me is our science and what we're showing in our data, and even with former programs, what we've done is special. There's a lot of potential, and I'm excited [about] how we've pivoted to in vivo [gene editing]. That's the future of gene editing and where it's going to have the biggest impact. A few months before the transition, I read an article about how women are well-positioned to be great CFOs even though it's been such a male-dominated field — it's about forming connections. I've seen that finance touches everything, that we're the lifeblood of the company. Beyond what people traditionally think of as the number crunching and investor outreach, what I'm excited about is being a part of the whole company and thinking strategically about not only their finances but everything they're doing. In biotech, you grow numb to operating at a loss. You're thinking more about cash runway and how to extend that. So while I was trained as an accountant, my financial acumen and strategy overpowers traditional accounting. My predecessor [former Editas CFO Erick Lucera], who set me to take the reins, instilled in me that the best cash is the cash you have. That's how I think about expenses and operating where we are, especially in these markets — being scrappy and capital efficient and making sure we're producing the best science with the best capital we have. Scrappy is being resourceful and rolling up your sleeves to do things that aren't necessarily in your job description or even where you've had formal training, but something you're excited about and committed to seeing through to the end. That's super important for biotech success. We don't have the luxury of a large headcount or huge infrastructure or resources, but that's motivating. The people who are scrappy are generally the ones who are motivated to move forward. There are lots of different flavors of gene editing. We can look at ex vivo gene editing, and Editas did have a phase 3 program. But there are lots of ways to deliver gene editing therapy — and we are moving from ex vivo to in vivo, and that's where the industry is at with gene editing. It's a fairly new technology, and so I think people need to understand how it works and how to think about it. There's been a lot of political uncertainty over the past few months, and we're all digesting what's being said and how to take that forward. It's been challenging to interpret that type of narrative and figure out what to do with it. So far, we haven't seen any ramifications of that rhetoric, and while the administration is fairly new in their tenure, once we understand what is being said or not being said, I think things will start to level out. We're always looking to the future. And while these are early-stage discussions for us, we're fortunate that we've seen companies like Vertex [Pharmaceuticals] and Bluebird [Bio] price their therapies on the market. There's a balance to figuring out the pricing for these therapies that can be a one-and-done treatment. I'm looking forward to thinking more about that, and we're using that as a guidepost. As the industry matures, we'll be part of it and mature with it. Recommended Reading Why layoffs are not the answer to biopharma's troubled market Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-05-2025
- Business
- Yahoo
Editas Medicine Announces First Quarter 2025 Results and Business Updates
Company to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) at ASGCT this week Company will also share in vivo preclinical proof of concept to upregulate expression of a target liver protein to meaningfully reduce a common disease-associated biomarker at ASGCT this week and TIDES next week Remains on track to declare two in vivo gene editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025 Strong cash position with operational runway into the second quarter of 2027 CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the first quarter 2025 and provided business updates. 'We achieved notable progress in the first quarter, advancing our mission and strategy to become a leader in in vivo gene editing. This momentum was fueled by recent scientific breakthroughs that bolster our confidence in the near-term potential of CRISPR-based in vivo gene editing therapies,' said Gilmore O'Neill, M.B., President and Chief Executive Officer of Editas Medicine. 'I'm proud of the strides made by the Editas team in driving our in vivo gene editing programs, which we believe could unlock significant new therapeutic possibilities. I look forward to our continued progress towards the clinic.' Dr. O'Neill continued, 'I am also thrilled to have welcomed Amy Parison to the executive leadership team as our CFO. Amy joined Editas in 2022 as our head of Finance, working closely with the CFO, and her track record of financial decision-making, accounting acumen, and team leadership abilities made her the natural choice for the role.' Recent Achievements and Outlook Upcoming Data Presentations Editas will present preclinical data to support its development of transformative in vivo gene editing medicines at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting on May 13-17. Presentations include: In Vivo Delivery of HBG1/2 Promoter Editing Cargo to HSC of Humanized Mouse and Non-Human Primate with Lipid Nanoparticles. In vivo CRISPR Editing of Genetic Regulatory Regions Results in Functional Upregulation of Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice. Design and Development of Improved LNP Targeting Ligands for in vivo Hematopoietic Stem Cell Editing. Design of Chemically Modified AsCas12a Guide RNAs for Increased Potency of LNP-Delivered Gene Editing Cargos. In vivo Gene Editing and Disease-Associated Biomarker Reduction for Multiple Liver Targets in Non-human Primate Using AsCas12a Nuclease Delivered by LNP. The Company will also present preclinical data and participate in panel presentations at TIDES USA 2025: Oligonucleotide & Peptide Therapeutics on May 19-22. Hematopoietic Stem Cells Editas will share in vivo preclinical data from humanized mouse and non-human primate (NHP) studies demonstrating the use of targeted lipid nanoparticles (tLNPs) to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) and/or hematopoietic stem cells (HSCs) in bone marrow at ASGCT on May 14. Liver Cells The Company will share preclinical proof of concept for an undisclosed liver target using in vivo CRISPR editing to upregulate target protein expression and reduce a disease-associated biomarker in a relevant mouse disease model at ASGCT on May 13 and the following week at the TIDES annual meeting. Additional proof of concept results from the first in vivo mouse and NHP studies demonstrate high levels of target gene editing in the liver and corresponding biomarker response following intravenous administration of AsCas12a messenger RNA (mRNA) and chemically modified guide RNAs (gRNAs) delivered using LNPs from the Company's collaborative partner Genevant. Platform Enhancements and Other Cells/Tissues Editas will share preclinical data demonstrating in vivo gene editing capabilities towards developing transformative in vivo medicines, including guide modification and targeting moiety optimizations to increase potency and improve gene editing outcomes in vivo at ASGCT. Additionally, the Company remains on track to establish and disclose one additional target cell type/tissue beyond HSCs and liver by year-end. Other Corporate Highlights Leadership Amy Parison Appointed Chief Financial OfficerMs. Parison has more than 18 years of financial, accounting, and business development experience in life sciences. During her time at Editas, she has served in multiple roles of increasing responsibilities including Senior Vice President, Finance, and Vice President and Corporate Controller. In partnership with the executive leadership team, she has worked on the Company's equity financings, licensing transactions and royalty monetization transaction. Prior to Editas, Ms. Parison served as Corporate Controller of Rubius Therapeutics where she led the accounting team following the Company's IPO, building critical business and financial processes. Prior to Rubius, she was at Vertex Pharmaceuticals, where she held several roles of increasing responsibility within the accounting and finance teams and supported forecasting, budgeting, and business development. She started her career with PricewaterhouseCoopers, LLP. Intellectual Property The U.S. Court of Appeals for the Federal Circuit vacated the Patent Trial and Appeal Board's (PTAB's) previous decision and remanded it back to the PTAB for further review in the U.S. patent interference involving specific patents for CRISPR/Cas9 editing in human cells between the University of California, the University of Vienna, and Emmanuelle Charpentier and the Broad Institute (Broad). We remain confident in our IP position and the strength of the Broad patents. First Quarter 2025 Financial ResultsCash, cash equivalents, and marketable securities as of March 31, 2025 were $221.0 million compared to $269.9 million as of December 31, 2024. The Company expects the existing cash, cash equivalents, and marketable securities and the retained portions of the payments payable under its license agreement with Vertex Pharmaceuticals, will enable the Company to fund its operating expenses and capital expenditure requirements into the second quarter of 2027. First Quarter 2025 For the three months ended March 31, 2025, net loss attributable to common stockholders was $76.1 million, or $0.92 per share, compared to net loss of $62.0 million, or $0.76 per share, for the same period in 2024. Collaboration and other research and development revenues increased to $4.7 million for the three months ended March 31, 2025, compared to $1.1 million for the same period in 2024. The increase is primarily attributable to the recognition of the remaining deferred revenue upon the closing out of a collaboration agreement with a strategic partner. Research and development expenses decreased by $22.2 million to $26.6 million for the three months ended March 31, 2025, compared to $48.8 million for the same period in 2024. The decrease is primarily related to clinical and manufacturing costs related to discontinuation of the clinical development of the Company's reni-cel program initiated in December 2024, partially offset by costs attributable to in vivo research and discovery. General and administrative expenses decreased by $6.0 million to $13.4 million for the three months ended March 31, 2025, compared to $19.3 million for the same period in 2024. The decrease is primarily related to stock-based compensation expenses related to expense in connection with the achievement of certain performance-based vesting of restricted stock units recognized in the first quarter of 2024 for which there was no equivalent expense in the first quarter of 2025. Restructuring and impairment charges were $40.9 million for the three months ended March 31, 2025, compared to no such charges for the same period in 2024. The restructuring and impairment charges were related to the discontinuation of the clinical development of the Company's reni-cel program initiated in December 2024, the related workforce reduction, associated impairment charges for laboratory and manufacturing equipment related to the reni-cel program and the acceleration in expense due to changes in useful life estimates for leasehold improvements, software and a right of use asset associated with the Company's reni-cel program. Upcoming Events Editas Medicine plans to participate in the following scientific and medical conferences: American Society of Gene and Cell Therapy (ASGCT) 28th Annual MeetingMay 13-17, 2025New Orleans, LA TIDES USA 2025: Oligonucleotide & Peptide TherapeuticsMay 19-22, 2025San Diego, CA Editas Medicine plans to participate in the following investor event: Bank of America Healthcare Conference 2025May 13, 2025Las Vegas, NV No Conference Call The Company is no longer hosting quarterly earnings conference calls. About Editas MedicineAs a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit Forward-Looking StatementsThis press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ''anticipate,'' ''believe,'' ''continue,'' ''could,'' ''estimate,'' ''expect,'' ''intend,'' ''may,'' ''plan,'' ''potential,'' ''predict,'' ''project,'' ''target,'' ''should,'' ''would,'' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the initiation, timing, progress and results of the Company's preclinical studies and its research and development programs, including the Company's expectation to declare two in vivo development candidates in mid-2025 and establish and disclose one additional in vivo target cell type/tissue beyond HSCs and the liver by the end of 2025; the timing for the Company's receipt and presentation of data from its preclinical studies; the potential of, and expectations for, the Company's in vivo product candidates; the timing or likelihood of regulatory filings and approvals; and the Company's expectations regarding cash runway into the second quarter of 2027. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation and completion of preclinical studies; availability and timing of results from preclinical studies; expectations for regulatory approvals to conduct trials; and the availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption 'Risk Factors' included in the Company's most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company's subsequent filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements. This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release. EDITAS MEDICINE, Statement of Operations(amounts in thousands, except share and per share data)(Unaudited) Three Months EndedMarch 31, 2025 2024 Collaboration and other research and development revenues $ 4,658 1,135 Operating expenses: Research and development 26,593 48,787 General and administrative 13,375 19,339 Restructuring and impairment charges 40,853 — Total operating expenses 80,821 68,126 Operating loss (76,163 ) (66,991 ) Other income, net: Other (expense) income, net (425 ) 6 Interest related to sale of future revenues (2,216 ) — Interest income, net 2,716 5,035 Total other income, net 75 5,041 Net loss $ (76,088 ) $ (61,950 ) Net loss per share, basic and diluted $ (0.92 ) $ (0.76 ) Weighted-average common shares outstanding, basic and diluted 83,055,066 81,938,839 EDITAS MEDICINE, Consolidated Balance Sheet Items(amounts in thousands)(Unaudited) March 31, December 31, 2025 2024 Cash, cash equivalents, and marketable securities $ 220,964 $ 269,913 Working capital 151,729 212,090 Total assets 263,652 341,589 Deferred revenue, net of current portion 54,204 54,204 Total stockholders' equity 62,420 134,274 CONTACT: Media and Investor Contact: ir@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-05-2025
- Business
- Yahoo
Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates
Editas Medicine (EDIT) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.76 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 15.69%. A quarter ago, it was expected that this genome editing company would post a loss of $0.39 per share when it actually produced a loss of $0.55, delivering a surprise of -41.03%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Editas , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $4.66 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 385.21%. This compares to year-ago revenues of $1.14 million. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Editas shares have added about 14.2% since the beginning of the year versus the S&P 500's decline of -3.8%. While Editas has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Editas: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.40 on $0.98 million in revenues for the coming quarter and -$1.53 on $6.74 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 34% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Lineage Cell (LCTX), has yet to report results for the quarter ended March 2025. The results are expected to be released on May 13. This biotechnology company is expected to post quarterly loss of $0.02 per share in its upcoming report, which represents a year-over-year change of +50%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Lineage Cell's revenues are expected to be $2.2 million, up 52.8% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Editas Medicine, Inc. (EDIT) : Free Stock Analysis Report Lineage Cell Therapeutics, Inc. (LCTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
